MARF/MFN Modulators for Mitochondrial Dysfunction Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively modulate mitochondrial regulatory proteins to treat diseases associated with mitochondrial dysfunction, such as familial neurological movement disorders, where aberrant autophagy and mitochondrial function lead to health defects and diseases like Parkinson's and Alzheimer's.
Innovation Solution
The use of mitofusin (Mfn) modulators, including nucleic acids, polypeptides, and small molecules like PROTACs, to regulate the expression or activity of proteins involved in autophagy, such as Vmp1 and Vps13D, to restore normal mitochondrial function and treat diseases related to mitochondrial dysfunction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current methods are used to treat mitochondrial dysfunction diseases, then treatment is provided, but the methods fail to effectively modulate mitochondrial regulatory proteins
Solution Approach 1:
The patent employs MARF/MFN modulators as intermediary molecules that specifically bind to and regulate mitochondrial regulatory proteins. These modulators act as mediators between the therapeutic agent and the target proteins, enabling effective modulation of mitochondrial function while maintaining manageable complexity through targeted molecular interactions.
Solution Approach 2:
The invention utilizes small molecule modulators that induce parameter changes in mitochondrial regulatory proteins by binding to specific sites and altering their conformational states, activity levels, or interaction patterns. This approach enables effective treatment through controlled changes in protein function parameters without requiring complex system-wide modifications.
2Reliability
If Mfn modulators are used to regulate autophagy proteins, then normal mitochondrial function is restored, but the complexity of the modulation system increases
Solution Approach 1:
The MARF/MFN modulators are designed with multi-functionality, capable of regulating multiple mitochondrial regulatory proteins and autophagy-related targets simultaneously. This universal approach restores normal mitochondrial function through a single modulator system that addresses multiple aspects of mitochondrial dysfunction, thereby reducing the need for multiple separate therapeutic agents.
Solution Approach 2:
The modulators serve as intermediary agents that translate therapeutic intent into specific molecular actions on mitochondrial proteins. By using these intermediary molecules, the system achieves reliable restoration of mitochondrial function while maintaining manageable complexity through well-defined molecular recognition and binding mechanisms.
3Manufacturing precision
If specific modulation of Marf or Mfn is achieved, then expression of autophagy proteins is regulated, but the precision requirements increase
Solution Approach 1:
The modulators exhibit local quality by specifically targeting particular domains or binding sites on MARF/MFN proteins, inducing conformational changes or regulatory effects at specific locations. This localized action enables precise regulation of autophagy protein expression with high specificity, achieving the desired precision through focused molecular interactions rather than global protein modification.
Solution Approach 2:
The invention replaces complex mechanical or genetic manipulation systems with small molecule modulators that achieve precise regulation through molecular recognition and binding. This substitution simplifies the modulation system while maintaining high precision, as the small molecules can specifically bind to and regulate target proteins through well-defined chemical interactions without requiring complex delivery or activation mechanisms.
Data Source
AI summary
Aspects of the disclosure relate to compositions and methods for modulating (e.g., inhibiting or promoting) expression of certain mitochondrial regulatory proteins, for example Marf and mitofusin (Mfn). The disclosure is based, in part, on modulation of Marf or Mfn to regulate expression or activity of certain proteins involved in autophagy, for example Vmp1 and vps13D. In some embodiments, compositions and methods described by the disclosure are useful for treating diseases related to aberrant autophagy or mitochondrial function, such as familial neurological movement disorders.